NurExone Biologic Reports Reduced Q2 Net Loss in 2026
NurExone Biologic (NRX:CA) reported a net loss of US$1.68 million for the second quarter of 2026, representing an improvement from the US$1.85 million loss recorded during the same period in 2025. The reduction in losses was primarily attributed to lower foreign currency translation adjustments and revaluation adjustments on royalty liabilities. Net financial expenses also decreased slightly to US$0.01 million compared to US$0.02 million a year earlier, reflecting more favorable conditions related to these factors. While the company has not disclosed broader operational or revenue figures in this release, the narrowing of losses suggests some progress in managing its financial position.
Tickers: $NRXBF
Topics: financial performance foreign currency adjustments net loss